Table 4.
Multivariate analysis of GRP78 rs391957 and clinical outcome in localized GA and locally advanced CRC
| GRP78 rs391957 | Localized GA |
Locally advanced CRC |
|||
| n | TTR | OS | n | TTR | |
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| CC | 63 | 1 (reference) | 1 (reference) | 88 | 1 (reference) |
| CT | 56a | 2.497 (1.261–4.946) | 2.390 (1.076–5.306) | 97 | 0.980 (0.568–1.691) |
| TT | 11a | 15 | 2.632 (1.214–5.708) | ||
| P valueb | 0.009 | 0.032 | 0.025 | ||
a
Combined in the analysis for TTR and OS in gastric cancer cohort.
b
Wald test in Cox proportional hazards model including T category and N category as covariates and stratified by race and type of chemotherapy for the localized GA cohort; Cox models included stage and type of adjuvant therapy as covariates and stratified by race in the locally advanced CRC cohort.
GRP78, 78-kiloDalton glucose-regulated protein; GA, gastric adenocarcinoma; CRC, colorectal cancer; TTR, time to tumor recurrence; OS, overall survival; HR, hazard ratio; CI, confidence interval.